Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and, finally, FDA post-market drug safety monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment,” a recent article reads. “A guide prepared by Bay Bridge Bio notes that a company’s valuation increases as its drug development progresses from phase I through phase III… Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (‘NDA’) regulatory pathway, an abbreviated pathway, the company’s drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course.”
To view the full article, visit https://cnw.fm/suldF
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text “HempWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Do you have questions or are you interested in working with HW? Ask our Editor
HempWire is part of the InvestorBrandNetwork.